Safety and Efficacy of COV795 in Moderate to Severe Post-Operative Bunionectomy Pain With an Open-label Extension
This study has been completed.
Information provided by (Responsible Party):
First received: November 28, 2011
Last updated: December 6, 2012
Last verified: December 2012
The primary objective of this study is to show the effectiveness of repeated doses of COV795 versus placebo, using the summed pain intensity difference over the first 48 hours in subjects with acute moderate to severe pain following bunionectomy.
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
||A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Evaluation of the Safety and Analgesic Efficacy of COV795 in Moderate to Severe Post-Operative Bunionectomy Pain Followed by an Open-Label Extension
Primary Outcome Measures:
Secondary Outcome Measures:
| Study Start Date:
| Study Completion Date:
| Primary Completion Date:
||August 2012 (Final data collection date for primary outcome measure)
2 tablets COV795 taken every 12 hours
Other Name: MNK795
Placebo Comparator: Placebo
2 placebo tablets taken every 12 hours
|Ages Eligible for Study:
||18 Years to 75 Years
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
- Complete the informed consent process as documented by signed informed consent form(s).
- Be in generally good health.
- Be 18 to 75 years of age, inclusively at the time of screening.
- Be scheduled for a primary unilateral first metatarsal bunionectomy (with no collateral procedures).
- Have a body mass index ≤33 kg/m2.
- Female subjects are eligible only if not pregnant, not lactating, not planning to become pregnant for the duration of the study, surgically sterile or at least two years postmenopausal, or practicing an acceptable form of birth control for at least 2 months
- Male subjects must be sterile or commit to the use of a reliable method of birth control
- Be classified as Physical status 1 (PS-1) to PS-2 by the American Society of Anesthetists (ASA) Physical Status Classification System.
- Be willing to complete the pain evaluations and return to the clinic as scheduled.
- Have an uncontrolled medical condition, serious intercurrent illness, clinically significant general health condition, or extenuating circumstance that may significantly decrease study compliance or otherwise preclude their participation in the study.
- Have a clinically significant abnormal electrocardiogram (ECG) at screening
- Have had any type of gastric bypass surgery or have a gastric band.
- Have previous abdominal surgery within the past year or history of abdominal adhesions, known or suspected paralytic ileus.
- Have a history of any medical condition that would alter the absorption, distribution, metabolism or excretion of COV795
- Have a history of severe bronchial asthma, hypercarbia, or hypoxia
- Have a clinically significant abnormality on their clinical laboratory values
- Have Addison's disease, benign prostatic hyperplasia, or kidney disease
- Have donated blood or blood components within 3 months prior to the screening visit.
- Have a known allergy or hypersensitivity to any opioid analgesics, anesthetics, acetaminophen, Non-steroid anti-inflammatory drugs (NSAIDs).
- Have a history of intolerance to short term opioid use.
- Unwilling to discontinue certain prohibited medications within the allotted time before surgery and throughout the duration of the study. Have taken certain drugs within the indicated times before surgery.
- Have a history of substance or alcohol abuse and/or a positive result on drug screening.
- Have a positive test for human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) at the screening visit.
- Have dysphagia and/or cannot swallow study medication whole.
- Have a history of migraine or frequent headaches, seizures, or are currently taking anticonvulsants.
- Have previously participated in a clinical trial using COV795 or had a bunionectomy in the last 3 months.
- Received any investigational drugs or devices within 4 weeks prior to the screening visit.
- Other criteria as specified in the trial protocol.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01484652
|Trovare Clinical Research, Inc.
|Bakersfield, California, United States, 93311 |
|Lotus Clinical Research, LLC
|Pasedena, California, United States, 91105 |
|Chesapeake Research Group, LLC
|Pasadena, Maryland, United States, 21122 |
|Endeavor Clinical Trials, PA
|San Antonio, Texas, United States, 78229 |
|Jean Brown Research, Inc.
|Salt Lake City, Utah, United States, 84124 |
No publications provided
History of Changes
|Other Study ID Numbers:
|Study First Received:
||November 28, 2011
||December 6, 2012
||United States: Food and Drug Administration
Keywords provided by Mallinckrodt:
Moderate Post-Operative Pain
Severe Post-Operative Pain
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on May 21, 2013
Signs and Symptoms